Article

Five genetic variants associated with prostate cancer

New England Journal of Medicine (Impact Factor: 54.42). 07/2008; 358(25):2738; author reply 2741. DOI: 10.1056/NEJMc080680
Source: PubMed
0 Followers
 · 
92 Views
 · 
1 Download
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Genome-wide association studies of hundreds of thousands of SNPs have led to a deluge of studies of genetic variation in cancer and other common diseases. Large case-control and cohort studies have identified novel SNPs as markers of cancer risk. Genome-wide association study SNP data have also advanced understanding of population-specific genetic variation. While studies of risk profiles, combinations of SNPs that may increase cancer risk, are not yet clinically applicable, future, large-scale studies will make individualized cancer screening and prevention possible.
    Personalized Medicine 12/2008; 5(6):589-597. DOI:10.2217/17410541.5.6.589 · 1.13 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The brisk discovery of novel inherited disease markers by genome-wide association (GWA) studies has raised expectations for predicting disease risk by analysing multiple common alleles. However, the statistics used during the discovery phase of research (such as odds ratios or p values for association) are not the most appropriate measures for evaluating the predictive value of genetic profiles. We argue that other measures--such as sensitivity, specificity, and positive and negative predictive values--are more useful when proposing a genetic profile for risk prediction.
    Nature Reviews Genetics 03/2009; 10(4):264-9. DOI:10.1038/nrg2516 · 39.79 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Advances in genomics promise to deliver personalized medicine both for prevention and treatment of disease. Considerable effort is being directed towards translating observed associations between various genetic variants, such as single nucleotide polymorphisms (SNPs), and disease or drug response into clinically useful genetic tests. Unfortunately, because reported associations are usually weak or moderate, tests based on them are generally not accurate enough for use in routine clinical practice, and therefore, ensuring the appropriate use of genetic tests is important. In a recent report, a combination of 5 SNPs was claimed to improve the predictive value of the test for prostate cancer, compared with the individual SNPs. This led the authors to suggest that a 5-SNP-test could be used to predict the risk of prostate cancer. We evaluate the characteristics of the proposed test, comment on it, and summarize the views of others on its potential clinical utility. We hope that this may serve as a case-example for the evaluation of the many new genetic tests being suggested for adoption.
    Public Health Genomics 06/2009; 13(1):55-62. DOI:10.1159/000218710 · 2.46 Impact Factor

Preview

Download
1 Download
Available from